BlackRock Inc. boosted its stake in shares of Repligen Co. (NASDAQ:RGEN) by 1.6% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,360,343 shares of the biotechnology company’s stock after purchasing an additional 81,858 shares during the quarter. BlackRock Inc. owned about 12.31% of Repligen worth $194,473,000 at the end of the most recent quarter.
A number of other institutional investors also recently made changes to their positions in RGEN. SG Americas Securities LLC bought a new stake in shares of Repligen in the third quarter valued at approximately $180,000. Crossmark Global Holdings Inc. bought a new stake in shares of Repligen in the third quarter valued at approximately $241,000. Brown Advisory Inc. bought a new stake in shares of Repligen in the third quarter valued at approximately $310,000. First Manhattan Co. boosted its position in shares of Repligen by 16.7% in the fourth quarter. First Manhattan Co. now owns 10,500 shares of the biotechnology company’s stock valued at $380,000 after acquiring an additional 1,500 shares during the period. Finally, Teacher Retirement System of Texas bought a new stake in shares of Repligen in the fourth quarter valued at approximately $462,000. 87.60% of the stock is owned by hedge funds and other institutional investors.
Repligen Co. (NASDAQ:RGEN) opened at $36.75 on Friday. The company has a debt-to-equity ratio of 0.17, a current ratio of 9.63 and a quick ratio of 8.08. The company has a market capitalization of $1,590.98, a price-to-earnings ratio of 51.76, a P/E/G ratio of 2.44 and a beta of 0.94. Repligen Co. has a 12 month low of $29.56 and a 12 month high of $46.81.
Repligen (NASDAQ:RGEN) last issued its earnings results on Thursday, February 22nd. The biotechnology company reported $0.20 EPS for the quarter, beating analysts’ consensus estimates of $0.12 by $0.08. The business had revenue of $41.60 million during the quarter, compared to analyst estimates of $41.13 million. Repligen had a return on equity of 7.08% and a net margin of 20.08%. Repligen’s revenue was up 62.5% on a year-over-year basis. During the same period in the prior year, the company posted $0.08 earnings per share. research analysts predict that Repligen Co. will post 0.7 EPS for the current fiscal year.
In related news, CEO Anthony Hunt sold 8,970 shares of the company’s stock in a transaction on Monday, January 22nd. The stock was sold at an average price of $35.95, for a total value of $322,471.50. Following the completion of the transaction, the chief executive officer now directly owns 83,613 shares in the company, valued at $3,005,887.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Thomas F. Ryan, Jr. sold 4,696 shares of the company’s stock in a transaction on Thursday, March 8th. The shares were sold at an average price of $36.16, for a total value of $169,807.36. Following the completion of the transaction, the director now owns 9,700 shares of the company’s stock, valued at $350,752. The disclosure for this sale can be found here. Corporate insiders own 1.50% of the company’s stock.
Several equities research analysts have recently weighed in on the company. Zacks Investment Research raised Repligen from a “sell” rating to a “hold” rating in a research report on Thursday, January 11th. BidaskClub cut Repligen from a “buy” rating to a “hold” rating in a research report on Wednesday, January 10th. TheStreet raised Repligen from a “c” rating to a “b-” rating in a research report on Tuesday, March 13th. Citigroup assumed coverage on Repligen in a research report on Friday, December 8th. They issued a “buy” rating and a $45.00 price objective for the company. Finally, JPMorgan Chase & Co. assumed coverage on Repligen in a research report on Tuesday, December 5th. They issued an “overweight” rating and a $42.00 price objective for the company. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $44.38.
COPYRIGHT VIOLATION NOTICE: “Repligen Co. (RGEN) Holdings Raised by BlackRock Inc.” was published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this story on another website, it was illegally stolen and republished in violation of US & international copyright and trademark law. The correct version of this story can be read at https://ledgergazette.com/2018/03/18/repligen-co-rgen-holdings-raised-by-blackrock-inc.html.
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.
Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN).
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.